Cargando…
Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide
Temozolomide (TMZ) is standard chemotherapy for glioblastoma multiforme (GBM). Intratumoral hypoxia is common in GBM and may be associated with the development of TMZ resistance. Oxygen therapy has previously been reported to potentiate the effect of chemotherapy in cancer. In this study, we investi...
Autores principales: | Sun, Stella, Lee, Derek, Lee, Nikki P., Pu, Jenny K. S., Wong, Stanley T. S., Lui, W. M., Fung, C. F., Leung, Gilberto K. K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434886/ https://www.ncbi.nlm.nih.gov/pubmed/22763762 http://dx.doi.org/10.1007/s11060-012-0923-3 |
Ejemplares similares
-
Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines
por: Sun, Stella, et al.
Publicado: (2011) -
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
por: Gallitto, Matthew, et al.
Publicado: (2020) -
A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia
por: Musah-Eroje, Ahmed, et al.
Publicado: (2019) -
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
por: Castro, Michael, et al.
Publicado: (2021) -
Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma
por: Shao, Naiyuan, et al.
Publicado: (2018)